Latest Mallinckrodt PLC News and Updates
Adage Capital adds a new position in Mallinckrodt
Adage Capital added a new position in Mallinckrodt Plc (MNK) in the third quarter of 2014. The position accounted for 0.82% of the fund’s total portfolio.
What Does Valeant’s Institutional Ownership Look Like?
Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.
Inside Mallinckrodt’s Major Valuation Catalysts
Acthar is Mallinckrodt’s (MNK) leading product, and the company plans to achieve mid-single-digit to low-double-digit growth for the drug in fiscal 2016.
The US Economy: Fischer and Brainard Weigh In
Stanley Fischer expressed his views on the US economy at the G30 Annual International Banking Seminar on October 11. This came three days after the dovish minutes of the FOMC September meeting.
Yes, There Will Be Margin Erosion for Valeant in 2017
Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.
Analyst Ratings for Endo International and Peers in August
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.
How Did Valeant Fare in 2Q16?
Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.
What Do Analysts Recommend for Valeant after Recent Happenings
The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.
Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016
Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.
Central Nervous System Is Key to Teva’s Specialty Medicines
Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.
A Look at Mallinckrodt’s Operating Segments
Mallinckrodt (MNK) is a specialty pharmaceuticals company that relies on volume-driven growth. Let’s discuss the performances of its three segments.
A key overview of Adage Capital’s holdings in 3Q14
Adage Capital’s US long portfolio grew from $38.69 billion in 2Q14 to $40.2 billion in 3Q14. The portfolio comprised around 699 stocks.
Kinder Morgan’s position with Adage Capital eliminated
Adage Capital exited a position in Kinder Morgan Inc (KMI) in the third quarter. The position accounted for 0.37% of the fund’s total 2Q portfolio.
Citigroup gets raised position with Adage Capital
Adage Capital raised its position in Citigroup Inc. (C) in the third quarter. The position accounted for 0.98% of the fund’s total 3Q portfolio.
Adage Capital raises its position in NiSource
Adage Capital raised its position in NiSource Inc. (NI) in the third quarter. The position accounted for 0.52% of the fund’s total 3Q14 portfolio.
Analysts’ Views on Endo International and Mallinckrodt
Most analysts covering Endo International (ENDP) and Mallinckrodt (MNK) recommend “hold.” On March 5, Endo closed at $8.72, and Mallinckrodt closed at $22.39.
Baxter International Completes Its Mallinckrodt Assets Buy
Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.
Performance of Incyte’s Jakafi in the United States
Revenues for Jakafi rose more than 42.0% to $852.8 million in 2016, from $601.0 million in 2015.
How Did Mallinckrodt’s Specialty Brands Perform in 2016?
Specialty Brands had a 69% in Mallinckrodt’s total revenue in 2016, while Specialty Generics had a 31% share.
Mallinckrodt’s Revenue Growth in Fiscal 4Q16
On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.
Valeant Looks to Boost Profit Margins through the Walgreens Deal
On December 15, 2015, Valeant Pharmaceuticals (VRX) announced its decision to enter into a fulfillment agreement with Walgreens.
Can Mallinckrodt Expand Its Margins?
Wall Street analysts expect Mallinckrodt’s (MNK) net margin to jump to 24.3% in 3Q16 from 10% in 3Q15.
The Truth behind Horizon’s EV-to-EBITDA Performance
On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.
Inside Neurocrine Biosciences’ Analyst Recommendations in 2016
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
The Facts behind the Valeant Drug Pricing Controversy
Valeant Pharmaceuticals International (VRX) significantly raised the prices of two of its heart drugs—Nitropress and Isuprel—which caused a controversy and an outrage.
What Happened in the Valeant-Philidor Controversy?
Valeant’s (VRX) controversies started with Philidor, a specialty pharmacy company that was accused of altering doctor’s prescriptions so it could sell more of Valeant’s costly drugs.
Defitelio: Volume and Pricing Challenges
Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).
Shire’s Acquisition Gives It Natpara and Gattex
Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.
Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know
Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.
How Horizon Became a Growth Stock
Over the past 18 months, Horizon Pharma has acquired three orphan drugs. The acquisition of Hyperion Therapeutics in May 2015 gave it Ravicti and Buphenyl.
Healthcare Stock Mallinckrodt Emerged as One of the Top Stocks
The stocks at the top of the SPDR S&P 500 ETF on December 30, 2015, were Allegheny Technologies (ATI), Mallinckrodt (MNK), and Tesoro Corporation (TSO).
J.M. Smucker Led the SPY ETF with a 7.0% Gain
J.M. Smucker posted EPS of $1.62, beating the consensus estimate of $1.52. It also reported net sales of ~$2.1 billion, in line with the market expectation.
PerkinElmer and Mallinckrodt Help Bottom Ten Stocks in XLV
PerkinElmer (PKI) with a return of 5.94% was the best performer of XLV’s bottom ten stocks.
Why Teva’s Generic Medicines Profitability Improved in 1Q15
Teva’s increased profitability for its generic medicines was partially offset by decreased profitability of its specialty medicines, which were down by 13% in 1Q15 from 1Q14.
High-Yield Bond Funds See Inflows Pick Up Pace in April 10 Week
The largest issuers of high-yield bonds in the primary market last week were Fiat Chrysler Automobiles, GM Financial, and Mallinckrodt International.
Fiat Chrysler, GM Financial Issue Largest Bonds in April 10 Week
Investors showed interest in high-yield bonds in the week ended April 10. Fiat Chrysler issued B2/BB- rated junk bonds worth $3 billion.
High-Yield Debt Issuance Gathers Steam in Week to April 10
In the week to April 10, junk bonds, or high-yield debt issuers, returned to the primary market. It was the same week the FOMC released its March 2015 meeting minutes.
Actavis Focuses on Complex Generics and Para IV Filings
In January 2015, Actavis launched a generic specialty injectable portfolio, containing ~20 products across its therapeutic segments in the US.
Adage Capital adds stake in Duke Energy
Adage Capital added a new position in Duke Energy in the third quarter. The position accounted for 0.20% of the fund’s total 3Q portfolio.
TRW Automotive Holdings is Adage Capital’s new position
Adage Capital added a new position in TRW Automotive Holdings, which accounted for 0.32% of the fund’s total 3Q14 portfolio.